European CHMP recommends paediatric license extension and paediatric formulations of dabigatran etexilate (Pradaxa)

Paediatric license extension, treatment of VTE and prevention of recurrent VTE from birth to <18 years of age, is supported by a new pharmaceutical form and strength – coated granules (20 mg, 30 mg, 40 mg, 50 mg, 110 mg, 150 mg) and oral solution (6.25 mg/ml).

Source:

European Medicines Agency